Invasive squamous cell carcinoma and sorafenib in a black patient

Archives of Dermatology

Volumn 147, Issue 1, 2011, Pages 133-134

  Donaldson, Matthew R ^a   Stetson, Cloyce L ^a   Smith, Jennifer L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADULT; ARTICLE; CANCER INVASION; CASE REPORT; DRUG DOSE REDUCTION; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CARCINOMA, SQUAMOUS CELL; DRUG ERUPTIONS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; SKIN NEOPLASMS;

EID: 78751563300     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.395     Document Type: Article

References (5)

1. Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol. 2007;56(1):171-172.
2. Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg. 2009;35(11):1766-1770.
3. Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol. 2009;61(3):522-527.
4. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
5. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27(23):e59-e61.